Chronic Lymphocytic Leukemia: Diagnosis and Treatment

被引：23
|
作者：
Strati, Paolo [1 ]
Jain, Nitin [2 ]
O'Brien, Susan [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA
来源：
MAYO CLINIC PROCEEDINGS | 2018年 / 93卷 / 05期
关键词：
B-CELL LYMPHOCYTOSIS; PREVIOUSLY UNTREATED PATIENTS; MINIMAL RESIDUAL DISEASE; SERUM THYMIDINE KINASE; PHASE-II TRIAL; INITIAL THERAPY; OPEN-LABEL; RICHTER TRANSFORMATION; 1ST-LINE TREATMENT; ZAP-70; EXPRESSION;
D O I：
10.1016/j.mayocp.2018.03.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The complexity of the treatment of patients with chronic lymphocytic leukemia has increased substantially over the past several years as a consequence of the advent of novel biological agents such as ibrutinib, idelalisib, and venetoclax, as well as increasingly potent anti-CD20 monoclonal antibodies. In addition, the identification of molecular predictive markers and the introduction of more sensitive and sophisticated techniques to assess minimal residual disease have allowed optimization of the use of chemo-immunotherapy and targeted therapies and may become standard of care in the future. This review summarizes the diagnosis, prognostication, and treatment of patients with chronic lymphocytic leukemia with emphasis on new prognostic and predictive factors and novel treatment strategies. (C) 2018 Mayo Foundation for Medical Education and Research
引用
收藏
页码：651 / 664
页数：14
相关论文
共 50 条
12345